Cargando…

JAK Inhibitors: Back to Small Molecules for the Treatment of IBD

Detalles Bibliográficos
Autores principales:	Panés, Julian, Vermeire, Severine
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Editorial
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7395305/ https://www.ncbi.nlm.nih.gov/pubmed/32737980 http://dx.doi.org/10.1093/ecco-jcc/jjaa109

Ejemplares similares

Efficacy, Safety and Future Perspectives of JAK Inhibitors in the IBD Treatment
por: Dudek, Patrycja, et al.
Publicado: (2021)

Clinical and Mechanistic Characteristics of Current JAK Inhibitors in IBD
por: Pippis, Elleni J, et al.
Publicado: (2020)

Big data in IBD: big progress for clinical practice
por: Seyed Tabib, Nasim Sadat, et al.
Publicado: (2020)

Short chain fatty acids and its producing organisms: An overlooked therapy for IBD?
por: Deleu, Sara, et al.
Publicado: (2021)

The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors
por: Bechman, Katie, et al.
Publicado: (2019)

Small Molecule Inhibitors of Interferon‐Induced JAK‐STAT Signalling
por: Thoidingjam, Leishemba K., et al.
Publicado: (2022)

New biologics and small molecules in inflammatory bowel disease: an update
por: Sabino, João, et al.
Publicado: (2019)

Suppression of Autoimmune Arthritis by Small Molecule Inhibitors of the JAK/STAT Pathway
por: Malemud, Charles J.
Publicado: (2010)

Novel Small Molecules in IBD: Current State and Future Perspectives
por: Jefremow, André, et al.
Publicado: (2023)

A New Horizon for Atopic Dermatitis Treatments: JAK Inhibitors
por: Tampa, Mircea, et al.
Publicado: (2023)

Tools for managing IBD in obese patients: Get JAK in the box!
por: Alrammah, Hanan M., et al.
Publicado: (2021)

GlycA, a Nuclear Magnetic Resonance Spectroscopy Measure for Protein Glycosylation, is a Viable Biomarker for Disease Activity in IBD
por: Dierckx, Tim, et al.
Publicado: (2019)

Distinct transcriptional signatures in purified circulating immune cells drive heterogeneity in disease location in IBD
por: Verstockt, Bram, et al.
Publicado: (2023)

Small Molecules as Protein-Protein Interaction Inhibitors
por: Hajimahdi, Zahra
Publicado: (2016)

IBD in the Time of COVID19
por: Moss, Alan, et al.
Publicado: (2020)

IBD in the elderly - beware of pitfalls!
por: Sharip, Mohmmed T., et al.
Publicado: (2023)

JAK Inhibitors — More Than Just Glucocorticoids
por: Stebbing, Justin, et al.
Publicado: (2021)

All in the family: back-to-back kinase inhibitors for the treatment of chronic lymphocytic leukemia
por: Thompson, Meghan C., et al.
Publicado: (2021)

Diet and Nutrition in IBD—Progress and Gaps
por: Raman, Maitreyi, et al.
Publicado: (2019)

Addressing Mental Health in Persons with IBD
por: Bernstein, Charles N
Publicado: (2018)

Primary sclerosing cholangitis is characterised by intestinal dysbiosis independent from IBD
por: Sabino, João, et al.
Publicado: (2016)

Monocyte TREM-1 Levels Associate With Anti-TNF Responsiveness in IBD Through Autophagy and Fcγ-Receptor Signaling Pathways
por: Prins, Marileen M., et al.
Publicado: (2021)

“Diet in the Etiopathogenesis of IBD: Is There A Culinary Culprit?”
por: Issokson, Kelly
Publicado: (2020)

Mycobacterium Avium Subspecies Paratuberculosis Infection and Biological Treatment of IBD: Cause or Consequence?
por: Proietti, E, et al.
Publicado: (2021)

Epidemiology and Natural History of IBD in the Paediatric Age
por: Guariso, Graziella, et al.
Publicado: (2014)

Personalized management of IBD; is there any practical approach?
por: Norouzinia, Mohsen, et al.
Publicado: (2015)

Is There a Best First Line Biological/Small Molecule in IBD: Are We Ready for Sequencing?
por: Hahn, Gustavo Drügg, et al.
Publicado: (2022)

Using IBD-REFER: A Substitute for Clinical Judgement?
por: Dueker, Jeffrey M, et al.
Publicado: (2020)

Novel Therapies and Approaches to Inflammatory Bowel Disease (IBD)
por: Furfaro, Federica, et al.
Publicado: (2022)

Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials
por: Cleynen, Isabelle, et al.
Publicado: (2019)

Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open
por: Biedermann, Luc, et al.
Publicado: (2022)

A new era for small molecule screening: from new targets, such as JAK2 V617F, to complex cellular screens
por: Constantinescu, Stefan N
Publicado: (2009)

Molecules after 20 Years—Looking Back and Looking Forward
por: McPhee, Derek J.
Publicado: (2015)

The JAK inhibitors: do they bring a paradigm shift for the management of rheumatic diseases?
por: Tanaka, Yoshiya
Publicado: (2019)

Risk/benefit trade-offs in rheumatology: rofecoxib revisited in the era of JAK inhibitors
por: Hazlewood, Glen S
Publicado: (2023)

The day after COVID-19 in IBD: how to go back to ‘normal’
por: Danese, Silvio, et al.
Publicado: (2020)

Personalised medicine in IBD: don’t dispose of the sledgehammer just yet
por: Kumar, Aditi, et al.
Publicado: (2022)

Corrigendum to “The new entries in the therapeutic armamentarium: The small molecule JAK inhibitors” [Pharmacol. Res. 147 (2019) 104392]
por: Bechman, Katie, et al.
Publicado: (2020)

Modified Mayo score versus Mayo score for evaluation of treatment efficacy in patients with ulcerative colitis: data from the tofacitinib OCTAVE program
por: Sandborn, William J., et al.
Publicado: (2022)

Identification of Novel Small Molecule Ligands for JAK2 Pseudokinase Domain
por: Virtanen, Anniina T., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_cgtufmu8r3pj5cn7b41r12flu9